Zhongyi Yang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 12

Top Topics

Endoplasmic Reticulum

Positron Emission Tomography

Top Venues

Annals of nuclear medicine

Molecular pharmaceutics

Breast cancer research : BCR

This page only lists publications with an associated author ORCID identifier.

Publications

Xinyue Du, Bingxin Gu, Xiao Wang, Xiangwei Wang, Mengjing Ji, Jianping Zhang, Simin He, Xiaoping Xu, Zhongyi Yang, Shaoli Song
Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II. Molecular pharmaceutics (2024)
Xinyue Du, Bingxin Gu, Xiao Wang, Xiangwei Wang, Mengjing Ji, Jianping Zhang, Simin He, Xiaoping Xu, Zhongyi Yang, Shaoli Song
Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II. Molecular pharmaceutics 21 (2) (2024)
Xinyue Du, Bingxin Gu, Xiao Wang, Xiangwei Wang, Mengjing Ji, Jianping Zhang, Simin He, Xiaoping Xu, Zhongyi Yang, Shaoli Song
Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [ 68 Ga]Ga-FAPI-FUSCC-II. Molecular pharmaceutics 21 (2) (2024)
Cheng Liu, Guang Ma, Jiangang Zhang, Jingyi Cheng, Zhongyi Yang, Shaoli Song
18 F-FES and 18 F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment. Annals of nuclear medicine (2023)
Xiao-Min Ou, Ruiping Zhai, Wenjun Wei, Jiaying Chen, Dan Ou, Tian Liao, Tingting Xu, Yongxue Zhu, Yu-Long Wang, Shengling Huang, Rongliang Shi, Bin Wu, Tongzhen Chen, Yuan Li, Zhongyi Yang, Changming Zhou, Yuan Liu, Ziting Jiang, Min Zeng, Xin Liu, Dongmei Ji, Hong-Mei Ying, Zhen Zhang, Chaosu Hu, Xueguan Lu, Qinghai Ji, Xiayun He, Yu Wang
Induction Toripalimab And Chemotherapy For Organ Preservation In Locally Advanced Laryngeal And Hypopharyngeal Cancer: A Single-Arm Phase 2 Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Yizhao Xie, Cheng Liu, Yannan Zhao, Chengcheng Gong, Yi Li, Shihui Hu, Shaoli Song, Xi-Chun Hu, Zhongyi Yang, Bi-Yun Wang
Heterogeneity derived from 18 F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients. Cancer medicine 11 (9) (2022)
Cheng Liu, Shihui Hu, Xiaoping Xu, Yongping Zhang, Biyun Wang, Shaoli Song, Zhongyi Yang
Evaluation of tumour heterogeneity by 18 F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment. Breast cancer research : BCR 24 (1) (2022)
Yizhao Xie, Xinyue Du, Yannan Zhao, Chengcheng Gong, Shihui Hu, Shuhui You, Shaoli Song, Xichun Hu, Zhongyi Yang, Bi-Yun Wang
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18 F-FES PET. Cancers 14 (14) (2022)
Chengcheng Gong, Cheng Liu, Zhonghua Tao, Jian Zhang, Leiping Wang, Jun Cao, Yannan Zhao, Yizhao Xie, Xichun Hu, Zhongyi Yang, Bi-Yun Wang
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18 F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancers 14 (16) (2022)
Cheng Liu, Ziyi Yang, Mingyu Liu, Xiangwei Wang, Shaoli Song, Xiaoping Xu, Zhongyi Yang
Gallium-68 Labeling of the Cyclin-Dependent Kinase 4/6 Inhibitors as Positron Emission Tomography Radiotracers for Tumor Imaging. ACS omega 6 (47) (2021)
Guang Ma, Bingxin Gu, Jiyi Hu, Lin Kong, Jiangang Zhang, Zili Li, Yangbo Xue, Jiade Lu, Junning Cao, Jingyi Cheng, Yingjian Zhang, Shaoli Song, Zhongyi Yang
Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. Annals of nuclear medicine 35 (7) (2021)
Guang Ma, Cheng Liu, Weiling Lian, Yongping Zhang, Huiyu Yuan, Yingjian Zhang, Shaoli Song, Zhongyi Yang
18F-FLT PET/CT imaging for early monitoring response to CDK4/6 inhibitor therapy in triple negative breast cancer. Annals of nuclear medicine 35 (5) (2021)